The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: A randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke

International Journal of Stroke

Volumn 9, Issue 2, 2014, Pages 246-251

  Bruno, Askiel ^a   Durkalski, Valerie L ^b   Hall, Christiana E ^c   Juneja, Rattan ^d   Barsan, William G ^e   Janis, Scott ^f   Meurer, William J ^e   Fansler, Amy ^g   Johnston, Karen C ^g  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acute ischemic stroke; Cerebral infarction; Clinical trial; Hyperglycemia; Protocols

Indexed keywords

GLUCOSE; HUMAN INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN INFUSION; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGLE BLIND PROCEDURE;

ACUTE ISCHEMIC STROKE; CEREBRAL INFARCTION; CLINICAL TRIAL; HYPERGLYCEMIA; PROTOCOLS;

ADULT; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84892697797     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12045     Document Type: Article

References (29)

1. Gentile NT, Seftchick MW, Huynh T, Kruus LK, Gaughan J. Decreased mortality by normalizing blood glucose after acute ischemic stroke. Acad Emerg Med 2006; 13:174-180.
2. Williams LS, Rotich J, Qi Retal. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002; 59:67-71.
3. Kruyt ND, Biessels GJ, Devries JH, Roos YB. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol 2010; 6:145-155.
4. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Normoglycemia (not hypoglycemia) optimizes outcome from middle cerebral artery occlusion. J Cereb Blood Flow Metab 1994; 14:227-236.
5. Meden P, Andersen M, Overgaard K, Rasmussen RS, Boysen G. The effects of early insulin treatment combined with thrombolysis in rat embolic stroke. Neurol Res 2002; 24:399-404.
6. Zhu CZ, Auer RN. Optimal blood glucose levels while using insulin to minimize the size of infarction in focal cerebral ischemia. J Neurosurg 2004; 101:664-668.
7. Ntaios G, Egli M, Faouzi M, Michel P. J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke 2010; 41:2366-2370.
8. Malmberg K, Ryden L, Efendic Setal. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65.
9. Van den Berghe G, Wilmer A, Hermans Getal. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461.
10. Bruno A, Kent TA, Coull BMetal. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 2008; 39:384-389.
11. Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR. Glucose regulation in acute stroke patients (GRASP) trial: a randomized pilot trial. Stroke 2009; 40:3804-3809.
12. Adams HP Jr, del Zoppo G, Alberts MJetal. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711.
13. Gray CS, Hildreth AJ, Sandercock PAetal. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK glucose insulin in stroke trial (GIST-UK). Lancet Neurol 2007; 6:397-406.
14. Kreisel SH, Berschin UM, Hammes HPetal. Pragmatic management of hyperglycaemia in acute ischaemic stroke: safety and feasibility of intensive intravenous insulin treatment. Cerebrovasc Dis 2009; 27:167-175.
15. Walters MR, Weir CJ, Lees KR. A randomised, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis 2006; 22:116-122.
16. Adams HP, Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis 2004; 18:124-129.
17. Adams HP, Jr, Effron MB, Torner Jetal. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke 2008; 39:87-99.
18. Bruno A, Waddell MJ, Potter DJetal. Opportunity to lower hyperglycaemia faster in patients with acute ischaemic stroke and diabetes. Int J Stroke 2010; 5:338-339.
19. Wong AA, Schluter PJ, Henderson RD, O'Sullivan JD, Read SJ. Natural history of blood glucose within the first 48 hours after ischemic stroke. Neurology 2008; 70:1036-1041.
20. Zhao W, Hill MD, Palesch Y. Minimal sufficient balance - a new strategy to balance baseline covariates and preserve randomness of treatment allocation. Stat Methods Med Res 2012, doi: 10.1177/0962280212436447.
21. Hu F, Rosenberger WF. The Theory of Response Adaptive Randomization in Clinical Trials. New York, Wiley, 2006.
22. Juneja R, Roudebush C, Kumar Netal. Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit. Diabetes Technol Ther 2007; 9:232-240.
23. Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42:1791-1798.
24. Williams LS, Weinberger M, Harris LE, Biller J. Measuring quality of life in a way that is meaningful to stroke patients. Neurology 1999; 53:1839-1843.
25. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
26. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS pilot trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke - II: neurologic outcome and efficacy analysis. Stroke 2006; 37:2107-2114.
27. Gould AL, Shih WJ. Modifying the design of ongoing trials without unblinding. Stat Med 1998; 17:89-100.
28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
29. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.